This article is for informational purposes only and does not constitute legal, tax, financial, or investment advice. Laws and regulations vary by jurisdiction and change frequently. Always consult a qualified professional before making any decision.
In June 2026, the Central Drugs Standard Control Organisation (CDSCO) has issued revised guidance on active pharmaceutical ingredient (API) purity and impurity profiling standards, applicable to both domestic manufacturers and importers. The guidance, effective immediately, tightens acceptance criteria for elemental impurities and process-related residues in APIs used in oral, injectable and topical formulations. Indian manufacturers and API importers must now align their analytical methods and batch-release protocols to these revised thresholds within 90 days of first application.
Market signals
CDSCO has harmonised its permitted limits for residual heavy metals (lead, cadmium, arsenic, mercury) with the International Council for Harmonisation (ICH) guideline Q3C(R2). This affects all APIs manufactured from June 2026 onwards and requires re-validation of existing supplier qualification dossiers.
Inductively coupled plasma mass spectrometry (ICP-MS) is now the mandated analytical method for quantifying residual solvents in APIs classified as Class 1 (solvents to avoid) and 2A (solvents with low toxic potential). Gas chromatography alone is no longer acceptable for these categories.
The 90-day transition period applies to new batch manufacture; existing stock may be cleared under the prior standard until expiry. However, importers face immediate scrutiny: CDSCO port laboratories will begin testing incoming API shipments against the new criteria from mid-June.
Under the Drugs and Cosmetics Rules, 1945, the CDSCO holds authority to prescribe acceptable standards for APIs; this June 2026 guidance is binding on all manufacturing licences issued under Rule 40 (manufacture) and Rule 41 (wholesale import). Non-compliance may result in product seizure, licence suspension, or import refusal. Manufacturers must immediately audit their analytical method validation reports (specifically ICH Q2(R1) and Q6A protocols) and verify supplier CoAs (Certificates of Analysis) against the new limits. Vinayakam Consultants assists pharma and chemical manufacturers with CDSCO submissions, including method validation strategy, supplier audit checklists, and batch-record documentation to meet these revised standards within the transition period.
Your action checklist
- Obtain the full CDSCO June 2026 API guidance document from the regulator's website; cross-reference elemental impurity thresholds and solvent limits against your current supplier CoAs and internal specifications.
- Instruct your analytical laboratory to validate or upgrade ICP-MS methods for Class 1 and 2A residual solvents by end of July 2026; retain full method validation reports (precision, accuracy, linearity, range) for CDSCO audit.
- Issue revised API specification sheets to all suppliers with effective date of 1 August 2026; request updated CoAs confirming compliance with new purity criteria, and conduct at least one verification batch from each supplier.
- Document and archive all batches manufactured under the prior standard through June 30, 2026; prepare a transition log for CDSCO, and flag any in-stock APIs that will expire after the new standard takes effect.
Frequently asked questions
CDSCO has revised guidance on active pharmaceutical ingredient purity and impurity profiling, tightening acceptance criteria for elemental impurities and process-related residues in APIs. Manufacturers and importers must align analytical methods within 90 days.
Inductively coupled plasma mass spectrometry (ICP-MS) is now the mandated method for quantifying residual solvents in Class 1 and 2A APIs. Gas chromatography alone is no longer acceptable.
Manufacturers have a 90-day transition period from first application to align batch-release protocols. Existing stock may be cleared under prior standards until expiry, but importers face immediate port laboratory scrutiny.